Qiagen Inks $225M Single-Cell Buyout as CEO Prepares to Step Down

Qiagen inks $225M single-cell buyout as CEO prepares to step down

Qiagen has identified Parse Biosciences’ technology as complementary to its sample technology and bioinformatic businesses.

QIAGEN acquires Parse Biosciences Inc for US$225m - European Biotechnology Magazine

Biotech leader QIAGEN NV announced the acquisition of Parse Biosciences for US$225M upfront, plus up to US$55M in milestone payments, expected to close by the end of 2025. QIAGEN acquires Parse Biosciences for US$225M, expanding platform-independent single-cell analysis and AI-driven workflows for drug discovery and research.